BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SG, Kim TY, Sohn JH, Um SH, Seo YS, Baik SK, Kim MY, Jang JY, Jeong SW, Lee B. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. Am J Gastroenterol. 2016;111:1582-1590. [PMID: 27575713 DOI: 10.1038/ajg.2016.327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Razafindrazoto CI, Razafindrabekoto LDE, Hasina Laingonirina DH, Raveloson R, Rasolonjatovo AS, Rakotozafindrabe ALR, Rabenjanahary TH, Razafimahefa SH, Ramanampamonjy RM. Carvedilol versus propranolol in the prevention of variceal rebleeding in hepatosplenic schistosomiasis: Efficacy and safety. JGH Open. [DOI: 10.1002/jgh3.12721] [Reference Citation Analysis]
2 de Mattos ÂZ, Terra C, Farias AQ, Bittencourt PL, Alliance of Brazilian Centers for Cirrhosis Care–the ABC Group. Primary prophylaxis of variceal bleeding in patients with cirrhosis: A comparison of different strategies. World J Gastrointest Endosc 2021; 13(12): 628-637 [DOI: 10.4253/wjge.v13.i12.628] [Reference Citation Analysis]
3 Paternostro R, Becker J, Hofer BS, Panagl V, Schiffke H, Simbrunner B, Semmler G, Schwabl P, Scheiner B, Bucsics T, Bauer D, Binter T, Trauner M, Mandorfer M, Reiberger T. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig Liver Dis 2021:S1590-8658(21)00778-7. [PMID: 34799282 DOI: 10.1016/j.dld.2021.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Fillipas-Ntekouan S, Fotopoulos A, Tsiouris S, Xourgia X, Lakkas L, Pappas K, Michalis LK, Sergianiti F, Baltayiannis G, Christodoulou D, Koustousi C, Aggelis N, Milionis H. Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. J Clin Gastroenterol 2021;55:721-9. [PMID: 32991355 DOI: 10.1097/MCG.0000000000001431] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Roccarina D, Best LM, Freeman SC, Roberts D, Cooper NJ, Sutton AJ, Benmassaoud A, Plaz Torres MC, Iogna Prat L, Csenar M, Arunan S, Begum T, Milne EJ, Tapp M, Pavlov CS, Davidson BR, Tsochatzis E, Williams NR, Gurusamy KS. Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2021;4:CD013121. [PMID: 33822357 DOI: 10.1002/14651858.CD013121.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tamarozzi F, Fittipaldo VA, Orth HM, Richter J, Buonfrate D, Riccardi N, Gobbi FG. Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature. PLoS Negl Trop Dis 2021;15:e0009191. [PMID: 33764979 DOI: 10.1371/journal.pntd.0009191] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Mohta S, Shalimar, Saraya A. Long-term Outcomes with Carvedilol versus Propranolol in Patients with Index Variceal Bleed: 6-year Follow-up Study. J Clin Exp Hepatol 2021;11:343-53. [PMID: 33994717 DOI: 10.1016/j.jceh.2020.08.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Jindal A, Bhardwaj A, Kumar G, Sarin SK. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg. Am J Gastroenterol 2020;115:1624-33. [PMID: 32453061 DOI: 10.14309/ajg.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Liu C, Liu Y, Shao R, Wang S, Wang G, Wang L, Zhang M, Hou J, Zhang C, Qi X. The predictive value of baseline hepatic venous pressure gradient for variceal rebleeding in cirrhotic patients receiving secondary prevention. Ann Transl Med 2020;8:91. [PMID: 32175384 DOI: 10.21037/atm.2019.12.143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
12 Fortea JI, Puente Á, Ruiz P, Ezcurra I, Vaquero J, Cuadrado A, Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, Rodríguez-Lope C, Huelin P, Casafont F, Fábrega E, Crespo J. Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. World J Clin Cases 2018; 6(13): 611-623 [PMID: 30430116 DOI: 10.12998/wjcc.v6.i13.611] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kim HY, So YH, Kim W, Ahn DW, Jung YJ, Woo H, Kim D, Kim MY, Baik SK. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol 2019;70:412-22. [PMID: 30389550 DOI: 10.1016/j.jhep.2018.10.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
14 Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018;10:CD011510. [PMID: 30372514 DOI: 10.1002/14651858.cd011510.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Karagiannakis DS, Voulgaris T, Siakavellas SI, Papatheodoridis GV, Vlachogiannakos J. Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. Scand J Gastroenterol 2018;53:1153-64. [PMID: 30345856 DOI: 10.1080/00365521.2018.1506046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Tripathi D, Stanley AJ. Editorial: optimal dose of carvedilol in portal hypertension…nearly there. Aliment Pharmacol Ther 2018;47:1328-9. [PMID: 29644737 DOI: 10.1111/apt.14607] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Kim SG, Larson JJ, Lee JS, Therneau TM, Kim WR. Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl. 2017;23:733-740. [PMID: 28187503 DOI: 10.1002/lt.24744] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
18 Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018;47:1162-1169. [PMID: 29492989 DOI: 10.1111/apt.14576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
19 Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, Peck-radosavljevic M, Ferlitsch A. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther 2018;47:86-94. [DOI: 10.1111/apt.14377] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
20 Mandorfer M, Reiberger T. Reply to: "Non selective beta blockers in cirrhosis". J Hepatol 2017;67:1343-4. [PMID: 28789883 DOI: 10.1016/j.jhep.2017.07.018] [Reference Citation Analysis]
21 Lo GH. Did Carvedilol Really Have More Severe Adverse Events than Propranolol in Cirrhotic Patients? Am J Gastroenterol 2017;112:808. [PMID: 28469221 DOI: 10.1038/ajg.2017.3] [Reference Citation Analysis]
22 Steib CJ, Gerbes AL. Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol. Hepatol Int 2017;11:141-2. [PMID: 28233256 DOI: 10.1007/s12072-017-9791-4] [Reference Citation Analysis]
23 Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49:3-10. [PMID: 27717792 DOI: 10.1016/j.dld.2016.09.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]